Germline MLH1 and MSH6 mutations from two Lynch syndrome families identified in a patient with early-onset of endometrial cancer: A case report

被引:0
|
作者
Huang, Yi-Ching [1 ]
Lin, Peng -Chan [1 ,2 ]
Wu, Pei-Ying [3 ]
Chen, Nai-Syuan [4 ]
Shen, Meng -Ru [3 ]
Yeh, Yu - Min [1 ]
Cheng, Ya-Min [3 ,5 ]
机构
[1] Natl Cheng Kung Univ Hosp, Dept Oncol, Tainan 704 138 Sheng-Li Rd, Tainan 138, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Genom Med, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan
[5] Kuo Gen Hosp, Superintendent, 22 Sec 2 Minsheng Rd, Tainan, Taiwan
来源
GYNECOLOGIC ONCOLOGY REPORTS | 2024年 / 53卷
关键词
Lynch syndrome; Endometrial cancer; Colorectal cancer; DNA mismatch repair; MLH1; MSH6;
D O I
10.1016/j.gore.2024.101381
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction: Lynch syndrome is caused by a germline mutation in mismatch repair (MMR) genes, leading to the loss of expression of MMR heterodimers, either MLH1/PMS2 or MSH2/MSH6, or isolated loss of PMS2 or MSH6. Concurrent loss of both heterodimers is uncommon, and patients carrying pathogenic variants affecting different MMR genes are rare, leading to the lack of cancer screening recommendation for these patients. Case presentation: Here, we reported a female with a family history of Lynch syndrome with MLH1 c.676C > T mutation. She developed endometrial cancer at 37 years old, with loss of MLH1/PMS2 expression. Immunohistochemical staining on tumor samples incidentally detected the additional loss of MSH6 expression. Whole exome sequencing on genomic DNA from peripheral blood revealed MSH6 c.2731C > T mutation, which was confirmed to be inherited from her mother, who had an early-onset ascending colon cancer without cancer family history. Conclusion: This is a rare case of the Lynch syndrome harboring germline mutations simultaneously in two different MMR genes inherited from two families with Lynch syndrome. The diagnosis of endometrial cancer at the age less than 40 years is uncommon for Lynch syndrome-related endometrial cancer. This suggests an earlier cancer screening for patients carrying two MMR mutations.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer
    Umegaki, Sho
    Takahashi, Masanobu
    Hasegawa-Minato, Junko
    Kawamura, Maako
    Taniguchi, Sakura
    Komine, Keigo
    Tokunaga, Hideki
    Ouchi, Kota
    Imai, Hiroo
    Saijo, Ken
    Shirota, Hidekazu
    Fujishima, Fumiyoshi
    Shimada, Muneaki
    Aoki, Yoko
    Ishioka, Chikashi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2025, 14 (02): : 171 - 176
  • [2] Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome
    Bonadona, Valerie
    Bonaiti, Bernard
    Olschwang, Sylviane
    Grandjouan, Sophie
    Huiart, Laetitia
    Longy, Michel
    Guimbaud, Rosine
    Buecher, Bruno
    Bignon, Yves-Jean
    Caron, Olivier
    Colas, Chrystelle
    Nogues, Catherine
    Lejeune-Dumoulin, Sophie
    Olivier-Faivre, Laurence
    Polycarpe-Osaer, Florence
    Nguyen, Tan Dat
    Desseigne, Francoise
    Saurin, Jean-Christophe
    Berthet, Pascaline
    Leroux, Dominique
    Duffour, Jacqueline
    Manouvrier, Sylvie
    Frebourg, Thierry
    Sobol, Hagay
    Lasset, Christine
    Bonaiti-Pellie, Catherine
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2304 - 2310
  • [3] Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome
    Schneider, Naye Balzan
    Pastor, Tatiane
    de Paula, Andre Escremim
    Achatz, Maria Isabel
    dos Santos, Andrea Ribeiro
    Luiz Vianna, Fernanda Sales
    Rosset, Clevia
    Pinheiro, Manuela
    Ashton-Prolla, Patricia
    Martins Moreira, Miguel Angelo
    Palmero, Edenir Inez
    CANCER MEDICINE, 2018, 7 (05): : 2078 - 2088
  • [4] Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer
    Karin Kast
    Teresa M Neuhann
    Heike Görgens
    Kerstin Becker
    Katja Keller
    Barbara Klink
    Daniela Aust
    Wolfgang Distler
    Evelin Schröck
    Hans K Schackert
    BMC Cancer, 12
  • [5] Two new MLH1 germline mutations in Brazilian lynch syndrome families
    Dominguez, M. V.
    Bastos, E. P.
    Santos, E. M. M.
    Oliveira, L. P.
    Ferreira, F. O.
    Carraro, D. M.
    Rossi, B. M.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (12) : 1263 - 1264
  • [6] Two new MLH1 germline mutations in Brazilian lynch syndrome families
    M. V. Dominguez
    E. P. Bastos
    E. M. M. Santos
    L. P. Oliveira
    F. O. Ferreira
    D. M. Carraro
    B. M. Rossi
    International Journal of Colorectal Disease, 2008, 23 : 1263 - 1264
  • [7] First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome
    Ziada-Bouchaar, H.
    Sifi, K.
    Filali, T.
    Hammada, T.
    Satta, D.
    Abadi, N.
    FAMILIAL CANCER, 2017, 16 (01) : 57 - 66
  • [8] Functional examination of MLH1, MSH2, and MSH6 intronic mutations identified in Danish colorectal cancer patients
    Petersen, Sanne M.
    Dandanell, Mette
    Rasmussen, Lene J.
    Gerdes, Anne-Marie
    Krogh, Lotte N.
    Bernstein, Inge
    Okkels, Henrik
    Wikman, Friedrik
    Nielsen, Finn C.
    Hansen, Thomas v O.
    BMC MEDICAL GENETICS, 2013, 14
  • [9] Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer
    Kast, Karin
    Neuhann, Teresa M.
    Goergens, Heike
    Becker, Kerstin
    Keller, Katja
    Klink, Barbara
    Aust, Daniela
    Distler, Wolfgang
    Schroeck, Evelin
    Schackert, Hans K.
    BMC CANCER, 2012, 12
  • [10] MSH6 germline mutations leading to Lynch syndrome-associated cholangiocarcinoma: a case report
    Zhang, Zheng
    Ma, Subo
    Li, Shixing
    Chen, Zhengfu
    Song, Runda
    Wang, Zhanpeng
    FRONTIERS IN ONCOLOGY, 2024, 14